Back to Browse Journals » Vascular Health and Risk Management » Volume 8

Effects of protein and omega-3 supplementation, provided during regular dialysis sessions, on nutritional and inflammatory indices in hemodialysis patients

Authors Mat Daud ZA, Tubie B, Adams J, Quainton T, Osia R, Tubie S, Kaur D, Khosla P, Sheyman M

Received 1 December 2011

Accepted for publication 8 February 2012

Published 20 March 2012 Volume 2012:8 Pages 187—195


Review by Single-blind

Peer reviewer comments 2

Zulfitri A Mat Daud1, Boniface Tubie2, Judy Adams2, Tracey Quainton2, Robert Osia2, Sharon Tubie2, Deepinder Kaur1, Pramod Khosla1, Marina Sheyman2
1Department of Nutrition and Food Science, Wayne State University, 2Great Lake Dialysis, LLC, Detroit, MI, USA

Purpose: Malnutrition and chronic inflammation in dialysis patients negatively impacts prognosis. However, intervening to correct this problem (through nutritional supplementation) is often hampered by poor compliance due to both medical and socioeconomic barriers. We have therefore performed a pilot study to investigate the technical feasibility of “directly observed treatment” of nutritional supplementation (protein and omega-3 fatty acids), administered during regular dialysis sessions. Secondary end points included observation of nutritional and inflammatory status of hypoalbuminemic patients undergoing hemodialysis.
Methods: Main inclusion criteria were serum albumin ≤ 3.9 g/dL (3 months prior to the study). Sixty-three eligible patients agreed to participate. Two intervention groups received 30 mL of a liquid protein supplement plus either 2.4 g omega-3 (1800 mg eicosapentaenoic acid + 600 mg docosahexaenoic acid) or a placebo, three times per week after their routine dialysis session for 6 months. Serum albumin, plasma lipids, and other indicators of nutritional and inflammatory status were measured.
Results: Directly observed nutritional supplementation resulted in a significant improvement in the low density lipoprotein cholesterol/high density lipoprotein cholesterol ratio in the omega-3 group as compared to the placebo group (P = 0.043). For the omega-3 group, serum albumin was also marginally higher after 6 months as compared to baseline (P = 0.07). The observed increase in C-reactive protein in the placebo group over 6 months was not apparent in the omega-3 group, although there was no significant difference between groups. Nuclear factor kappa B, malnutrition-inflammation score, normalized protein nitrogen appearance, body mass index, and hemoglobin were unaffected by the intervention.
Conclusion: “Directly observed treatment” with an omega-3 based supplement (as opposed to a pure protein supplement) showed beneficial effects on the lipid profile, and C-reactive protein levels. Further studies using a combination of outpatient and inpatient “directly observed treatment” of omega-3 based supplementation is warranted.

Keywords: protein and omega-3 supplementation, inflammation, nutritional status, hemodialysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] View Full Text [HTML] 


Other article by this author:

Vitamin E tocotrienol supplementation improves lipid profiles in chronic hemodialysis patients

Daud ZAM, Tubie B, Sheyman M, Osia R, Adams J, Tubie S, Khosla P

Vascular Health and Risk Management 2013, 9:747-761

Published Date: 28 November 2013

Readers of this article also read:

Tear osmolarity and dry eye symptoms in diabetics

Fuerst N, Langelier N, Massaro-Giordano M, Pistilli M, Stasi K, Burns C, Cardillo S, Bunya VY

Clinical Ophthalmology 2014, 8:507-515

Published Date: 10 March 2014

Endoglin: a critical mediator of cardiovascular health

Kapur NK, Morine KJ, Letarte M

Vascular Health and Risk Management 2013, 9:195-206

Published Date: 6 May 2013

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients

Nielsen SA, McDonald MB, Majmudar PA

Clinical Ophthalmology 2013, 7:149-156

Published Date: 17 January 2013

Ocular hypertension after intravitreal triamcinolone with vitrectomy and phacoemulsification

Parke III DW, Sisk RA, Houston SK, Murray TG

Clinical Ophthalmology 2012, 6:925-931

Published Date: 18 June 2012

Effects of a 6-month exercise program pilot study on walking economy, peak physiological characteristics, and walking performance in patients with peripheral arterial disease

Crowther RG, Leicht AS, Spinks WL, Sangla K, Quigley F, Golledge J

Vascular Health and Risk Management 2012, 8:225-232

Published Date: 17 April 2012

Dexamethasone intravitreal implant for the treatment of noninfectious uveitis

Hunter RS, Lobo AM

Clinical Ophthalmology 2011, 5:1613-1621

Published Date: 11 November 2011

Screening for type 2 diabetes in a multiethnic setting using known risk factors to identify those at high risk: a cross-sectional study

Laura J Gray, Jennifer R Tringham, Melanie J Davies, et al

Vascular Health and Risk Management 2010, 6:837-842

Published Date: 20 September 2010

Early seizures in patients with acute stroke: Frequency, predictive factors, and effect on clinical outcome

Andrea Alberti, Maurizio Paciaroni, Valeria Caso, Michele Venti, Francesco Palmerini, Giancarlo Agnelli

Vascular Health and Risk Management 2008, 4:715-720

Published Date: 6 June 2008

Peripapillary detachment in pathologic myopia: Unusual OCT findings

Michele Carbonelli, Giacomo Savini, Maurizio Zanini, Piero Barboni
Centro Salus, Bologna, Italy

Clinical Ophthalmology 2007, 1:327-329

Published Date: 15 December 2007